Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients, Clinical Infectious Diseases, vol.34, issue.7, pp.909-917, 2002. ,
DOI : 10.1086/339202
The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole, American Journal of Hematology, vol.53, issue.4, pp.283-288, 2013. ,
DOI : 10.1002/ajh.23388
Update on the epidemiology and diagnosis of invasive fungal infection, Int J Antimicrob Agents, vol.32, pp.143-147, 2008. ,
and Its Interaction with Azole Antifungals, Journal of Medicinal Chemistry, vol.43, issue.13, pp.2493-2505, 2000. ,
DOI : 10.1021/jm990589g
Antifungal serum concentration monitoring: an update, Journal of Antimicrobial Chemotherapy, vol.61, issue.1 ,
DOI : 10.1093/jac/dkm389
Polymorphism of human cytochrome P450 enzymes and its clinical impact, Drug Metabolism Reviews, vol.288, issue.1, pp.89-295, 2009. ,
DOI : 10.1124/mol.104.008086
Inhibition of Voriconazole Metabolism by Chloramphenicol in an Adolescent with Central Nervous System Aspergillosis, Antimicrobial Agents and Chemotherapy, vol.52, issue.11, pp.4172-4174, 2008. ,
DOI : 10.1128/AAC.00805-08
Effect of food on the pharmacokinetics of multiple-dose oral voriconazole, British Journal of Clinical Pharmacology, vol.691, pp.17-23, 2003. ,
DOI : 10.1046/j.1365-2125.2003.01994.x
Potential Factors for Inadequate Voriconazole Plasma Concentrations in Intensive Care Unit Patients and Patients with Hematological Malignancies, Antimicrobial Agents and Chemotherapy, vol.57, issue.7, pp.3262-3267, 2013. ,
DOI : 10.1128/AAC.00251-13
Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes, Clinical Infectious Diseases, vol.46, issue.2, pp.201-211, 2008. ,
DOI : 10.1086/524669
Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics-Based Analysis of Adult Patients With Invasive Fungal Infections, Clinical Infectious Diseases, vol.55, issue.3, pp.381-390, 2012. ,
DOI : 10.1093/cid/cis437
Voriconazole Therapeutic Drug Monitoring, Antimicrobial Agents and Chemotherapy, vol.50, issue.4, pp.1570-1572, 2006. ,
DOI : 10.1128/AAC.50.4.1570-1572.2006
Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial, BMC Infect Dis. Clin Infect Dis Off Publ Infect Dis Soc Am, vol.1355, pp.1080-1087, 2012. ,
Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring, Antimicrobial Agents and Chemotherapy, vol.56, issue.9, pp.4793-4799, 2012. ,
DOI : 10.1128/AAC.00626-12
Influence of Human Serum on Antifungal Pharmacodynamics with Candida albicans, Antimicrobial Agents and Chemotherapy, vol.45, issue.7, pp.2018-2022, 2001. ,
DOI : 10.1128/AAC.45.7.2018-2022.2001
Pharmacokinetic/Pharmacodynamic Profile of Voriconazole, Clinical Pharmacokinetics, vol.26, issue.7, pp.649-663, 2006. ,
DOI : 10.2165/00003088-200645070-00002
Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?, Cancer Chemotherapy and Pharmacology, vol.62, issue.Suppl 4, pp.531-536, 2013. ,
DOI : 10.1007/s00280-012-2035-3
Evidence-based implementation of free phenytoin therapeutic drug monitoring, Clin Chem, vol.46, pp.1132-1135, 2000. ,
Effect of protein binding on the activity of voriconazole alone or combined with anidulafungin against Aspergillus spp. using a time-kill methodology, Rev Esp Quimioter Publ Of Soc Esp Quimioter, vol.25, pp.47-55, 2012. ,
Yeasts in the gut: from commensals to infectious agents, Dtsch Ärztebl Int, vol.106, pp.837-842, 2009. ,
Aspergillosis, New England Journal of Medicine, vol.360, issue.18, pp.1870-1884, 2009. ,
DOI : 10.1056/NEJMra0808853
Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient, Rev Esp Quimioter Publ Of Soc Esp Quimioter, vol.26, pp.173-188, 2013. ,
The Epidemiology of Sepsis in the United States from 1979 through 2000, New England Journal of Medicine, vol.348, issue.16, pp.1546-1554, 1979. ,
DOI : 10.1056/NEJMoa022139
Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study, Mycoses, vol.56, pp.638-645, 2013. ,
double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation, Blood, vol.116, pp.5111-5118, 2010. ,
Volatile metabolites produced by six fungal species compared with other indicators of fungal growth on cereal grains, Appl Environ Microbiol, vol.58, pp.2599-2605, 1992. ,
Antifungal drug resistance to azoles and polyenes, The Lancet Infectious Diseases, vol.2, issue.9, pp.550-563, 2002. ,
DOI : 10.1016/S1473-3099(02)00371-7
Three-Dimensional Model of Lanosterol 14??-Demethylase from Cryptococcus neoformans: Active-Site Characterization and Insights into Azole Binding, Antimicrobial Agents and Chemotherapy, vol.53, issue.8, pp.3487-3495, 2009. ,
DOI : 10.1128/AAC.01630-08
Azole affinity of sterol 14?- demethylase (CYP51) enzymes from Candida albicans and Homo sapiens ,
Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 ,
In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of Zygomycetes, Antimicrobial Agents and Chemotherapy, vol.46, issue.5, pp.1581-1582, 2002. ,
DOI : 10.1128/AAC.46.5.1581-1582.2002
In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program, Diagnostic Microbiology and Infectious Disease, vol.48, issue.3, pp.201-205, 2004. ,
DOI : 10.1016/j.diagmicrobio.2003.09.008
Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole, Journal of Antimicrobial Chemotherapy, vol.42, issue.2, pp.253-256, 1998. ,
DOI : 10.1093/jac/42.2.253
In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts, Antimicrobial Agents and Chemotherapy, vol.50, issue.6, pp.2009-2015, 2006. ,
DOI : 10.1128/AAC.00163-06
Differential expression of ATP-binding cassette and/or major facilitator superfamily class efflux pumps contributes to voriconazole resistance in Aspergillus flavus, Diagnostic Microbiology and Infectious Disease, vol.76, issue.4, pp.458-463, 2013. ,
DOI : 10.1016/j.diagmicrobio.2013.04.022
Azole Resistance of Aspergillus fumigatus Biofilms Is Partly Associated with Efflux Pump Activity, Antimicrobial Agents and Chemotherapy, vol.55, issue.5, pp.2092-2097, 2011. ,
DOI : 10.1128/AAC.01189-10
Molecular basis of resistance to azole antifungals, Trends in Molecular Medicine, vol.8, issue.2, pp.76-81, 2002. ,
DOI : 10.1016/S1471-4914(02)02280-3
Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene, Microbiology, vol.143, issue.2, pp.405-416, 1997. ,
DOI : 10.1099/00221287-143-2-405
Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis, Antimicrob Agents Chemother, vol.42, pp.2932-2937, 1998. ,
Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in Candida albicans Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected Patients, Antimicrobial Agents and Chemotherapy, vol.45, issue.10, pp.2676-2684, 2001. ,
DOI : 10.1128/AAC.45.10.2676-2684.2001
A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans, Journal of Antimicrobial Chemotherapy, vol.53, issue.2, pp.386-389, 2004. ,
DOI : 10.1093/jac/dkh066
Effects of Double and Triple Combinations of Antifungal Drugs in a Murine Model of Disseminated Infection by Scedosporium prolificans, Antimicrobial Agents and Chemotherapy, vol.53, issue.5, pp.2153-2155, 2009. ,
DOI : 10.1128/AAC.01477-08
Efficacy of Caspofungin and Voriconazole Combinations in Experimental Aspergillosis, Antimicrobial Agents and Chemotherapy, vol.49, issue.9, pp.3697-3701, 2005. ,
DOI : 10.1128/AAC.49.9.3697-3701.2005
Comparative Efficacies of Conventional Amphotericin B, Liposomal Amphotericin B (AmBisome), Caspofungin, Micafungin, and Voriconazole Alone and in Combination against Experimental Murine Central Nervous System Aspergillosis, Antimicrobial Agents and Chemotherapy, vol.49, issue.12, pp.4867-4875, 2005. ,
DOI : 10.1128/AAC.49.12.4867-4875.2005
Pharmacocinétique (PK)/pharmacodynamie (PD) et place du suivi thérapeutique pharmacologique (STP) des antifongiques. Médecine thérapeutique, pp.329-339, 2010. ,
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients, Cancer, vol.44, issue.8, pp.1532-1535, 2007. ,
DOI : 10.1002/cncr.22568
Molecular properties impact on bioavailability of second generation triazoles antifungal agents, Acta Pol Pharm, vol.70, pp.869-872, 2013. ,
metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype, Br J Clin Pharmacol, vol.68, pp.906-915, 2009. ,
Human tissue distribution of voriconazole, Antimicrob Agents Chemother, vol.55, pp.925-928, 2011. ,
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism, Clinical Pharmacokinetics, vol.32, issue.4, pp.913-958, 2002. ,
DOI : 10.2165/00003088-200241120-00002
CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole, J Clin Pharmacol, vol.49, pp.196-204, 2009. ,
Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers, The Journal of Clinical Pharmacology, vol.13, issue.2-3, pp.195-203, 2011. ,
DOI : 10.1177/0091270010395510
In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3 In vivo evaluation of Michaelis-Menten constants of hepatic drug-eliminating systems, Drug Metab Dispos Biol Fate Chem. Drug Metab Dispos Biol Fate Chem, vol.386, pp.25-31197, 1978. ,
Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function, J Chemother Florence Italy, vol.20, pp.93-100, 2008. ,
Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy, BMC Clinical Pharmacology, vol.56, issue.Suppl 1, p.6, 2006. ,
DOI : 10.1046/j.1365-2125.2003.01993.x
safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies, Clin Drug Investig, vol.28, pp.409-420, 2008. ,
Administration of Voriconazole in Patients With Renal Dysfunction, Clinical Infectious Diseases, vol.54, issue.7, pp.913-921, 2012. ,
DOI : 10.1093/cid/cir969
Evaluation of the effect of obesity on voriconazole serum concentrations, Journal of Antimicrobial Chemotherapy, vol.67, issue.12, pp.2957-2962, 2012. ,
DOI : 10.1093/jac/dks312
Systemic antifungal drug interactions, J de Myc Med, pp.152-158, 2006. ,
Effect of omeprazole on the steady-state pharmacokinetics of voriconazole, Br J Clin Pharmacol, vol.1356, pp.56-61, 2003. ,
Utilization of Omeprazole To Augment Subtherapeutic Voriconazole Concentrations for Treatment of Aspergillus Infections, Antimicrobial Agents and Chemotherapy, vol.56, issue.11, pp.6001-6002, 2012. ,
DOI : 10.1128/AAC.00700-12
Guidelines for the Diagnosis And Treatment of Acute And Chronic Heart Failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM), Rev Esp Cardiol Engl Ed, vol.61, issue.82, p.1329, 2008. ,
NEORAL MONITORING BY SIMPLIFIED SPARSE SAMPLING AREA UNDER THE CONCENTRATION-TIME CURVE, Transplantation, vol.68, issue.1 ,
DOI : 10.1097/00007890-199907150-00011
Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients, Journal of Clinical Oncology, vol.18, issue.6, pp.1173-11780, 2000. ,
DOI : 10.1200/JCO.2000.18.6.1173
Voriconazole concentrations and outcome of invasive fungal infections, Clinical Microbiology and Infection, vol.16, issue.7, pp.927-933, 2010. ,
DOI : 10.1111/j.1469-0691.2009.02990.x
Retrospective Serological Tests for Determining the Optimal Blood Concentration of Voriconazole for Treating Fungal Infection, YAKUGAKU ZASSHI, vol.128, issue.12, pp.1811-1818, 2008. ,
DOI : 10.1248/yakushi.128.1811
Safety of Voriconazole and Dose Individualization, Clinical Infectious Diseases, vol.36, issue.8, pp.1087-1088, 2003. ,
DOI : 10.1086/374248
Is free plasmatic cortisol measurement useful in intensive care unit? In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis, Ann Biol Clin. J Pharm Sci, vol.66102, pp.31-412882, 2008. ,
Determination of unbound drug concentration and protein-drug binding fraction in plasma, Biomedical Chromatography, vol.13, issue.4, pp.262-266, 1999. ,
DOI : 10.1002/(SICI)1099-0801(199906)13:4<262::AID-BMC832>3.0.CO;2-2
Protocols for use of ultrafiltration in determination of free ligand concentration and of complexity of ligand/protein interactions, Clin Chem, vol.33, pp.115-117, 1987. ,
Determination of unbound fraction of imatinib and N-desmethyl imatinib, validation of an UPLC???MS/MS assay and ultrafiltration method, Journal of Chromatography B, vol.907, pp.94-100, 2012. ,
DOI : 10.1016/j.jchromb.2012.09.007
Displacement of one drug by another from carrier or receptor sites ,
Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia, Clin Chem, vol.43, pp.2274-2280, 1997. ,
Free drug monitoring, Clin Lab Med, vol.7, pp.279-287, 1987. ,
Serum Concentrations of Free Diphenylhydantoin and their Relationship To Clinical Intoxication, Epilepsia, vol.13, issue.2, pp.177-184, 1973. ,
DOI : 10.1111/j.1528-1157.1973.tb03954.x
Apparent Valproic Acid Neurotoxicity in a Hypoalbuminemic Patient, Annals of Pharmacotherapy, vol.27, issue.1, pp.32-35, 1993. ,
DOI : 10.1177/106002809302700107
Elevated Free Fractions of Valproic Acid in a Heart Transplant Patient with Hypoalbuminemia, Annals of Pharmacotherapy, vol.274, issue.2, pp.183-187, 2000. ,
DOI : 10.1345/aph.19147
Value of therapeutic drug level monitoring and unbound (free) levels, Seizure, vol.17, issue.6, pp.572-575, 2008. ,
DOI : 10.1016/j.seizure.2007.12.007
Phenytoin Toxicity Associated With Hypoalbuminemia in Critically Ill Patients, Chest, vol.105, issue.2, pp.602-604, 1994. ,
DOI : 10.1378/chest.105.2.602
A Rational Basis for the Measurement of Free Phenytoin Concentration in Critically I11 Trauma Patients, Therapeutic Drug Monitoring, vol.16, issue.2, pp.139-144, 1994. ,
DOI : 10.1097/00007691-199404000-00005
Distribution of Cyclosporin in Organ Transplant Recipients, Clinical Pharmacokinetics, vol.3, issue.9 ,
DOI : 10.2165/00003088-200241090-00001
Changes in Tacrolimus Distribution in Blood and Plasma Protein Binding Following Liver Transplantation, Therapeutic Drug Monitoring, vol.26, issue.5, pp.506-515, 2004. ,
DOI : 10.1097/00007691-200410000-00008
Factors affecting variability in distribution of tacrolimus in liver transplant recipients, British Journal of Clinical Pharmacology, vol.30, issue.3, pp.298-309, 2004. ,
DOI : 10.1046/j.1365-2125.2003.02008.x
Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant, British Journal of Clinical Pharmacology, vol.11, issue.3, pp.271-280, 2005. ,
DOI : 10.1034/j.1399-0012.2001.150607.x
High Unbound Mycophenolic Acid Concentrations in a Hematopoietic Cell Transplantation Patient with Sepsis and Renal and Hepatic Dysfunction, Biology of Blood and Marrow Transplantation, vol.11, issue.12, pp.977-978, 2005. ,
DOI : 10.1016/j.bbmt.2005.08.037
New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis, J Clin Microbiol, vol.37, pp.1510-1517, 1999. ,
Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity, Clinica Chimica Acta, vol.424, pp.119-122, 2013. ,
DOI : 10.1016/j.cca.2013.05.025
Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes, International Journal of Antimicrobial Agents, vol.34, issue.1, pp.91-94, 2009. ,
DOI : 10.1016/j.ijantimicag.2009.01.008
Free renal levels of voriconazole determined by microdialysis in healthy and Candida sp.-infected Wistar rats, International Journal of Antimicrobial Agents, vol.33, issue.2, pp.154-159, 2009. ,
DOI : 10.1016/j.ijantimicag.2008.08.020
Changes in plasma protein binding have little clinical relevance, Clinical Pharmacology & Therapeutics, vol.71, issue.3, pp.115-121, 2002. ,
DOI : 10.1067/mcp.2002.121829
The Clinical Relevance of Plasma Protein Binding Changes, Clinical Pharmacokinetics, vol.3, issue.2, pp.1-8, 2013. ,
DOI : 10.1007/s40262-012-0018-5
Plamsa protein binding displacement interactions are no longer what they used to be, La let du Pharmaco, pp.44-60, 2012. ,
110 Neurological adverse events to voriconazole: Evidence for therapeutic drug monitoring, International Journal of Infectious Diseases, vol.10, pp.739-742, 2006. ,
DOI : 10.1016/S1201-9712(06)80107-4
A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients, Clin Cancer ANNEXES Annexe, vol.1 ,